10x - דינמיקת הכנסות משנה לשנה ב-12 החודשים האחרונים TXG

The stability of 10x Genomics, Inc. (TXG) is based on the sale of high-cost equipment and high-margin consumables for DNA analysis. Year-over-year (TTM) sales growth confirms this trend, with the indicator holding at -3.60. However, expansion is complicated by patent wars and fierce competition for laboratory budgets, as well as the emergence of technological alternatives in the field of spatial biology.
10x Genomics Inc - פילוחים אנליטיים ומדדי מפתח (TXG)

10x Genomics, Inc. (TXG) maintains its leadership in single-cell analysis, yet the current slowdown in laboratory expansion and rising marketing costs are pressuring margins. By analyzing the trailing twelve months (TTM) sales volume change, an investor can track rolling annual revenue dynamics, which provides a real-time assessment of fundamental value and allows for the timely detection of revenue stagnation prior to the publication of quarterly reports.